KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Operating Expenses data on record, last reported at $213.9 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 76.16% year-over-year to $213.9 million; the TTM value through Dec 2025 reached $3.0 billion, down 10.07%, while the annual FY2025 figure was $4.7 billion, 40.14% up from the prior year.
  • Operating Expenses reached $213.9 million in Q4 2025 per JAZZ's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.7 billion in Q2 2025 and bottomed at $213.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $856.4 million, with a median of $824.4 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: soared 125.47% in 2021, then crashed 76.16% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $847.4 million in 2021, then skyrocketed by 45.81% to $1.2 billion in 2022, then dropped by 28.01% to $889.4 million in 2023, then grew by 0.9% to $897.4 million in 2024, then crashed by 76.16% to $213.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $213.9 million in Q4 2025, $1.1 billion in Q3 2025, and $1.7 billion in Q2 2025.